Table 1.

DTaP and DTP Vaccine Efficacy Against Mild and Typical Pertussis* due to B pertussis, B parapertussis and Either Organism Combined

Primary Case Definitions
VaccinesB pertussis-SpecificB parapertussis-SpecificEither B pertussis or B parapertussis
No. CasesRateEfficacy (95% CI)No. CasesRateEfficacy (95% CI)No. CasesRateEfficacy (95% CI)
DTaP851.072%540.631%1391.663%
(62 –79)(−10 –56)(53 –71)
DTP500.683%810.9−6%1321.564%
(76 –88)(−64 –31)(55 –72)
DT 103 3.4 27 0.9 130 4.4
238162401
  • * Cough illness of ≥7 days' duration.

  • Isolation of B pertussis by culture or significant ELISA antibody rise to PT or a household contact to a B pertussisculture confirmed case.

  • Isolation of B parapertussis by culture or significant ELISA antibody rise to FHA or pertactin or a significant agglutinin response or a household contact to a B parapertussis culture confirmed case and no ELISA antibody response to PT.

  • Isolation of either B pertussis or B parapertussis or serologic evidence of infection with either organism or household contact with a culture confirmed illness due to either organism.

  • Cases per 100 person years.